Abstract:

Objective To observes the efficacy of the four nucleot(s)ide analogues including lamivudine, adefovir, entecavir and telbivudine in treatment of HBV-induced decompensated cirrhosis. Methods Patients with HBV-induced decompensated hepatitis B cirrhosis treated with and without nucleot(s)ide analogues(NAs) were followed up for a median of 11 months. HBV DNA, liver function, Child-Pugh-Turcotte scores, and MELD scores. Results A total of 52 patients were enrolled in this study after excluding 59 patients out of 111 patients with HBV-induced decompensated hepatitis B cirrhosis. Forty patients were assigned into the NAs group and 12 patients into the control group. In the control group, the HBV DNA, ALT, AST, ALB, TBIL, CHE, INR, Child-Pugh scores and MELD scores had no improvement between as compared with the baseline values and the end-of-follow up values. In the NAs group, the HBV DNA, ALT, ALB, CHE, INR, Child-Pugh scores had significant improvement(P<0.05) and AST, TBIL, MELD scores had no improvement(P＞0.05). Conclusion Nucleot(s)ide analogues could suppress HBV replication, improve liver function,stabilize or even reverse the development of decompensated cirrhosis and be welltolerated. Further studies are needed to observe the longterm efficacy and the rate of liver cancer development.

Key words: nucleot(s)ide analogues, antiviral therapy, decompensated hepatic cirrhosis, hepatitis B virus